Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

What this episode covers

Visit https://www.peervoice.com/HTG860 to view the entire programme with slides. After completing “Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy”, participants will be able to: Describe the clinical rationale for oral selective estrogen receptor degraders (SERDs) for patients with ER+, HER2- advanced breast cancer; Evaluate the evidence with emerging oral SERDs for the management of ER+, HER2- advanced breast cancer; and Outline evidence-based clinical strategies to address endocrine resistance for patients with ER+, HER2- advanced breast cancer.

Distinct summary based on available episode metadata or transcript content.